JP2011523935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523935A5 JP2011523935A5 JP2010547761A JP2010547761A JP2011523935A5 JP 2011523935 A5 JP2011523935 A5 JP 2011523935A5 JP 2010547761 A JP2010547761 A JP 2010547761A JP 2010547761 A JP2010547761 A JP 2010547761A JP 2011523935 A5 JP2011523935 A5 JP 2011523935A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- chemical denervation
- pharmaceutical composition
- denervation
- nachr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 230000002638 denervation Effects 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 28
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 16
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 210000003205 muscle Anatomy 0.000 claims description 10
- 101000822793 Ophiophagus hannah Alpha-elapitoxin-Oh2b Proteins 0.000 claims description 9
- 101000822779 Ophiophagus hannah Long neurotoxin 4 Proteins 0.000 claims description 9
- 101000822798 Ophiophagus hannah Long neurotoxin OH-5 Proteins 0.000 claims description 9
- 101000963936 Pseudonaja textilis Short neurotoxin N1 Proteins 0.000 claims description 9
- 101000963941 Pseudonaja textilis Short neurotoxin N2 Proteins 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- 230000001242 postsynaptic effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims description 6
- 210000000225 synapse Anatomy 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 231100000189 neurotoxic Toxicity 0.000 claims description 4
- 230000002887 neurotoxic effect Effects 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims description 2
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002427 irreversible effect Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6634708P | 2008-02-19 | 2008-02-19 | |
| US61/066,347 | 2008-02-19 | ||
| PCT/US2009/034578 WO2009105585A2 (en) | 2008-02-19 | 2009-02-19 | Postsynaptically targeted chemodenervation agents and their methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011523935A JP2011523935A (ja) | 2011-08-25 |
| JP2011523935A5 true JP2011523935A5 (https=) | 2013-04-11 |
Family
ID=40986187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547761A Pending JP2011523935A (ja) | 2008-02-19 | 2009-02-19 | シナプス後部を標的とした化学的除神経剤およびそれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9815875B2 (https=) |
| EP (1) | EP2250193B1 (https=) |
| JP (1) | JP2011523935A (https=) |
| CN (1) | CN102007142A (https=) |
| AU (1) | AU2009215436A1 (https=) |
| CA (1) | CA2754352A1 (https=) |
| ES (1) | ES2757648T3 (https=) |
| IL (1) | IL207631A0 (https=) |
| WO (1) | WO2009105585A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7259237B1 (en) | 2006-12-29 | 2007-08-21 | Miller Kent D | Pan-antiviral peptides |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| WO2011053937A2 (en) * | 2009-10-30 | 2011-05-05 | Bayer Healthcare Llc | Antibody mimetic scaffolds |
| US9220743B2 (en) | 2010-01-22 | 2015-12-29 | Nuovo Biologics, Llc | Pan-antiviral peptides for protein kinase inhibition |
| CN103145799B (zh) * | 2013-02-18 | 2014-04-16 | 大连理工大学 | 一组具有促进经皮和跨膜渗透作用的多肽及其应用 |
| CN104232653B (zh) * | 2014-09-19 | 2017-04-05 | 中南大学湘雅医院 | 重组α‑银环蛇毒素αBtx的制备方法 |
| KR20190137781A (ko) | 2017-02-07 | 2019-12-11 | 마이오셉트 인코포레이티드 | 국소 제제 및 방법 |
| CN110090296A (zh) * | 2018-09-21 | 2019-08-06 | 祁展楷 | 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用 |
| JP2022514114A (ja) | 2018-10-16 | 2022-02-09 | ジーエルオー ファーマ，インク． | ニコチン性アセチルコリン受容体ペプチドアンタゴニストであるコノトキシン組成物、およびこれに関連する方法 |
| CN113474357A (zh) * | 2018-12-21 | 2021-10-01 | 非营利性组织佛兰芒综合大学生物技术研究所 | 具有毒素和支架蛋白的融合蛋白 |
| EP3753568A1 (en) * | 2019-06-21 | 2020-12-23 | Fastox Pharma SA | Composition modulating botulinum neurotoxin effect |
| CN110478473B (zh) * | 2019-07-14 | 2025-08-12 | 江苏毫末医药生物科技有限公司 | 眼镜蛇神经毒素多肽对鸦片类药品痛觉过敏和耐受的抑制及对其镇痛的协同增效作用 |
| CN116997350A (zh) * | 2019-10-11 | 2023-11-03 | 祁展楷 | 眼镜蛇科蛇突触后神经毒素单体分子在治疗老年痴呆上的应用 |
| US20230062487A1 (en) * | 2020-01-24 | 2023-03-02 | W. L. Gore & Associates, Inc. | Sustained-release matrices for adventitial or periadventitial neural ablation and uses thereof |
| CN111544571A (zh) * | 2020-06-02 | 2020-08-18 | 沈喆景 | 眼镜蛇科蛇突触后神经毒素在治疗与炎性细胞因子过度表达相关疾病的应用 |
| CN114409757B (zh) * | 2022-01-26 | 2023-07-18 | 云南南诏药业有限公司 | 一种蛇毒神经毒素及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447356A (en) * | 1981-04-17 | 1984-05-08 | Olivera Baldomero M | Conotoxins |
| FR2762009B1 (fr) * | 1997-04-10 | 1999-06-04 | Commissariat Energie Atomique | Enzymes recombinantes purifiees a activite prolylpeptidasique, leur procede de preparation et leurs applications |
| IL143379A (en) * | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
| CA2584643C (en) * | 2004-11-02 | 2013-01-29 | Pentapharm Ag | New, topically applicable actives against mimic and age-related wrinkles |
| WO2007035474A2 (en) * | 2005-09-15 | 2007-03-29 | Novomed Technologies, Inc. (Shanghai) | Transdermal delivery peptides and method of use thereof |
| US7659252B2 (en) * | 2005-09-15 | 2010-02-09 | Novomed Technologies, Inc. (Shanghai) | Transdermal delivery peptides and method of use thereof |
-
2009
- 2009-02-19 EP EP09713319.3A patent/EP2250193B1/en active Active
- 2009-02-19 CA CA2754352A patent/CA2754352A1/en not_active Abandoned
- 2009-02-19 AU AU2009215436A patent/AU2009215436A1/en not_active Abandoned
- 2009-02-19 WO PCT/US2009/034578 patent/WO2009105585A2/en not_active Ceased
- 2009-02-19 US US12/867,975 patent/US9815875B2/en not_active Expired - Fee Related
- 2009-02-19 ES ES09713319T patent/ES2757648T3/es active Active
- 2009-02-19 CN CN2009801144924A patent/CN102007142A/zh active Pending
- 2009-02-19 JP JP2010547761A patent/JP2011523935A/ja active Pending
-
2010
- 2010-08-16 IL IL207631A patent/IL207631A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523935A5 (https=) | ||
| CA2704651C (en) | Use of melanocortins to treat insulin sensitivity | |
| US9062125B2 (en) | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission | |
| HRP20160020T1 (hr) | Postupak za aktiviranje pomagaäśke t stanice i pripravak za uporabu u postupku | |
| JP6279626B2 (ja) | エンドモルフィンのμオピオイド受容体アゴニスト類似体 | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| CA2873553C (en) | Use of modified vasoactive intestinal peptides in the treatment of hypertension | |
| EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| US20150299286A1 (en) | Glutamic acid-stabilized insulin analogues | |
| JP2009533355A5 (https=) | ||
| EP4389216A2 (en) | Peptide compositions and therapeutic uses | |
| JP2004537581A5 (https=) | ||
| US20170369531A1 (en) | Mu opioid receptor agonist analogs of the endomorphins | |
| RU2010128602A (ru) | Циклический белок, не содержащий остатков цистеина | |
| PT2717896T (pt) | Agentes terapêuticos para a regulação do fósforo sérico | |
| AU2025202528A1 (en) | Compositions for treating kidney disease | |
| CN104031141A (zh) | 用于治疗2型糖尿病的长效肠激素多肽类似物及应用 | |
| RU2018145945A (ru) | Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма | |
| JP2012529423A5 (https=) | ||
| CA2470235C (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| KR20230171400A (ko) | 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드 | |
| JP2019520336A5 (https=) | ||
| US20210171604A1 (en) | Peptides for the treatment of type 2 diabetes |